Your browser is no longer supported. Please, upgrade your browser.
TIL [NASD]
Instil Bio, Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own6.91% Shs Outstand128.79M Perf Week-8.70%
Market Cap2.63B Forward P/E- EPS next Y-1.64 Insider Trans0.00% Shs Float120.03M Perf Month7.04%
Income-118.60M PEG- EPS next Q-0.45 Inst Own56.00% Short Float3.75% Perf Quarter1.90%
Sales0.05M P/S51655.93 EPS this Y-478.60% Inst Trans2.04% Short Ratio14.47 Perf Half Y14.44%
Book/sh4.67 P/B4.36 EPS next Y-22.30% ROA- Target Price30.00 Perf Year-
Cash/sh3.99 P/C5.11 EPS next 5Y- ROE- 52W Range14.42 - 29.49 Perf YTD-22.96%
Dividend- P/FCF- EPS past 5Y- ROI85.30% 52W High-30.93% Beta-
Dividend %- Quick Ratio16.30 Sales past 5Y- Gross Margin- 52W Low41.26% ATR1.70
Employees150 Current Ratio16.30 Sales Q/Q- Oper. Margin- RSI (14)49.93 Volatility13.49% 8.74%
OptionableNo Debt/Eq0.00 EPS Q/Q22.20% Profit Margin- Rel Volume1.29 Prev Close19.86
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume310.84K Price20.37
Recom1.80 SMA20-3.40% SMA502.03% SMA2006.04% Volume400,012 Change2.57%
Aug-13-21Initiated Robert W. Baird Outperform $34
Apr-13-21Initiated Truist Buy $32
Apr-13-21Initiated Morgan Stanley Equal-Weight $24
Apr-13-21Initiated Cowen Outperform
Nov-15-21 07:00AM  
07:00AM  
Nov-10-21 11:28AM  
Nov-08-21 08:05AM  
Sep-16-21 07:00AM  
Sep-15-21 04:27PM  
Sep-13-21 07:00AM  
Sep-02-21 07:00AM  
Aug-12-21 07:00AM  
Jul-19-21 02:34PM  
Jun-21-21 10:06AM  
Jun-01-21 07:00AM  
May-13-21 07:00AM  
Apr-29-21 08:45AM  
Apr-27-21 07:00AM  
Apr-12-21 07:18AM  
Mar-23-21 05:00PM  
Mar-19-21 04:25PM  
Mar-18-21 08:26PM  
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McGaughy R Kent JrDirectorMar 23Buy20.00450,0009,000,0008,478,790Mar 25 05:28 PM
Vivo Capital IX, LLC10% OwnerMar 23Buy20.00300,0006,000,00012,486,787Mar 25 05:32 PM
Crouch BronsonCEO and ChairmanMar 23Buy20.00450,0009,000,00037,980,073Mar 25 04:27 PM